Antimicrobial susceptibility testing of 230 Helicobacter pylori strains: Importance of medium, inoculum, and incubation time

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 12, 1997, Pages 2634-2639

  Hartzen, S Hartvig ^a,d   Andersen, L Percival ^a   Bremmelgaard, A ^a   Colding, H ^a   Arpi, M ^a   Kristiansen, J ^b   Justesen, T ^a   Espersen, F ^c   Frimodt Moller N ^c   Bonnevie, O ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Sønderborg Hospital   (Denmark)

^c STATENS SERUM INSTITUT   (Denmark)

^d NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; AMOXICILLIN; ANTIINFECTIVE AGENT; CIPROFLOXACIN; CLARITHROMYCIN; METRONIDAZOLE; TETRACYCLINE; TOBRAMYCIN SULFATE;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BLOOD; COLONY FORMING UNIT; CONTROLLED STUDY; CULTURE MEDIUM; DENMARK; DILUTION; HELICOBACTER PYLORI; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0030833029     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.12.2634     Document Type: Article

References (28)

1. Adamek, R. J., S. Suerbaum, B. Pfaffenbach, and M. Wegener. 1996. Influence of H. pylori resistance to antibiotics on eradication outcome. Gut 39(Suppl. 2):A5 (abstr. 1A:02).
2. Andersen, L. P. Personal communication.
3. Andreasen, J. J., and L. P. Andersen. 1987. In vitro susceptibility of Campylobacter pyloridis to cimetidine, sucralfate, bismuth and sixteen antibiotics. Acta Pathol. Microbiol. Immuno. Scand. Sect. B 95:147-149.
4. Banatvala, N., G. Davies, Y. Abdi, I. Clements, D. Rampton, J. Hardie, and R. Feldman. 1994. High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease. Gut. 35:1562-1566.
5. Blaser, M. 1995. Helicobacter pylori and related organisms. In G. Mandell, R. Douglas, and J. Bennett. (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, New York, N.Y.
6. Bouchard, S., C. Birac, H. Lamouliatte, S. Forestier, and F. Megraud. 1996. Correlation between the MICs of metronidazole on Helicobacter pylori strains and the outcome of a lansoprazole-amoxicillin-melronidazole therapy. Gut 39(Suppl. 2):A6 (abstr. 1A:05).
7. Coudron, P., and C. Stratton. 1995. Factors affecting growth and susceptibility testing of Helicobacter pylori in liquid media. J. Clin. Microbiol. 33:1028-1030.
8. Czinn, S., H. Carr, and S. Aronoff. 1986. Susceptibility of Campylobacter pyloridis to three macrolide antibiotics (erythromycin, roxithromycin [RU28965], and CP 62,993) and rifampin. Antimicrob. Agents Chemother. 30:328-329.
9. Czinn, S. J., H. Carr, and V. Hupertz. 1989. Susceptibility of Campylobacter pylori to newer cephalorin antibiotics. Chemotherapy (Basel) 35:164-167.
10. DeCross, A., B. Marshall, R. McCallum, S. Hoffman, L. Barrett, and R. Guerrant. 1993. Metronidazole susceptibility testing for Helicobacter pylori: comparison of disk, broth, and agar dilution methods and their clinical relevance. J. Clin. Microbiol. 31:1971-1974.
11. Garcia-Rodriguez, J., J. Garcia Sanchez, M. Garcia Garcia, E. Garcia Sanchez, and J. Munoz Bellido. 1989. In vitro activities of new oral β-lactams and macrolides against Campylobacter pylori. Antimicrob. Agents Chemother. 33:1650-1651.
12. Gisbert, J. P., D. Boixeda, L. De Rafael, L. Moreno, C. Martin de Argila, F. Bermejo, and C. Redondo. 1996. Which factors influence on the success of "classic" triple therapy in Helicobacter pylori eradication? Gut 39(Suppl. 2):A7 (abstr. 1A:11).
13. Glupczynski, Y., M. Delmee, C. Bruck, M. Labbé, V. Avesani, and A. Burette. 1988. Susceptibility of clinical isolates of Campylobacter pylori to 24 antimicrobial and anti-ulcer agents. Eur. J. Epidemiol. 4:154-157.
14. Glupczynski, Y., S. Goutier, C. Vandenborre, J. P. Butzler, and A. Burette. 1995. Surveillance of Helicobacter pylori resistance to antimicrobial agents in Belgium 1989-1994, abstr. E96, p. 103. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
15. Goddard, A., and R. Logan. 1996. Antimicrobial resistance and Helicobacter pylori. J. Antimicrob. Chemother. 37:639-643.
16. Hardy, D., C. Hanson, D. Hensey, J. Beyer, and P. Fernandes. 1988. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. J. Antimicrob. Chemother. 22:631-636.
17. Karim, Q. N., and R. P. H. Logan. 1995. The epidemiology of Helicobacter pylori (H. pylori) antimicrobial resistance - preliminary findings of a national survey. Gut 37(Suppl. 2):A6.
18. Lambert, T., F. Megraud, G. Gerbaud, and P. Courvalin. 1986. Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents. Antimicrob. Agents Chemother. 30:510-511.
19. McNulty, C., J. Dent, and R. Wise. 1985. Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrob. Agents Chemother. 28:837-838.
20. McNulty, C., and J. Dent. 1988. Susceptibility of clinical isolates of Camnpylobacter pylori to twenty-one antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. 7:566-569.
21. Mera, S. L. 1995. Peptic ulcers and gastric cancers. Br. J. Biomed. Sci. 52:271-281.
22. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. 1994. Helicobacter pylori in Peptic Ulcer Disease. JAMA 272:65-69.
23. Oxoid. 1990. Oxoid manual. Oxoid, Basingstoke, United Kingdom.
24. Peitz, U., A. Nusch, E. Tillenburg, M. Stolte, G. Börsch, and J. Labenz. 1996. High cure rate of H. pylori (HP) infection by one-week therapy with omeprazole (OME), metronidazole (MET), and clarithromycin (CLA) despite negative impart MET resistance. Gut 39(Suppl. 2):A5 (abstr. 1A:03).
25. Reyn, A., and M. W. Bentzon. 1972. Comparison of a selective and a non-selective medium in the diagnosis of gonorrhoea to ascertain the sensitivity of Neisseria gonorrhoeae to vancomycin. Br. J. Vener. Dis. 48: 363-368.
26. Simor, A., S. Ferro, and D, Low. 1989. Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori. Antimicrob. Agents Chemother. 33:108-109.
27. Working Group on the Evaluation of Carcinogenic Risks to Humans. 1994. Schistosomiasis, liver flukes and Helicobacter pylori, p. 177-241. International Agency for Research on Cancer. World Health Organization, Lyon, France.
28. Xia, H., M. Buckley, C. Keane, and C. O'Morain. 1996. Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in ritro. J. Antimicrob. Chemother. 37:473-481.